Kisho

GB002, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc. — Rare Disease Pipeline | Kisho

GB002, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc.

Other

Orphan Designations

0 approved, 1 designated

FDA Approvals

Active Trials

200 recruiting

Rare Diseases

across 2 areas

News (30d)

Quiet

GB002, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc. is a company with 1 orphan drug designation across 2 rare diseases. Active clinical trials in 2 indications.

Competitive Landscape

Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.

Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA

Approved: 0

In Trials: 1

Designated Only: 1

2 total diseases

Disease	Drug(s)	Stage
pulmonary arterial hypertension	(S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium	Des.TrialAppr.
pulmonary hypertension	-	Des.TrialAppr.